Antibody therapeutics company Arana Therapeutics Ltd announced in a Monday press release that it has been awarded a patent by the European Patent Office for Evibodies, small antibody-like proteins that can be used as drugs or diagnostic agents in applications where whole antibodies may be unsuitable.
European patent, No. 1058728 covers the company’s development and use of Evibodies, adding to the Arana technology platform by supplying a means of discovering new targeting agents.
The granted patent has been validated in the following European countries: Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Switzerland, Sweden, Spain and UK and has now passed the time-limited opposition period.
“This patent represents another important milestone for Arana Therapeutics. We were actively developing Evibodies due to their key benefit of being synergistic with the company’s other technology capabilities,” Acting CEO of Arana Steffen Nock said.
“The grant of this patent supports the continued development of Evibodies, further strengthening and expanding Arana’s technology platform,” he added.
Evibodies are only about one tenth the size of an antibody and can therefore be manufactured more economically.
Arana Therapeutics is a biopharmaceutical company focused on developing next generation antibody based drugs that will improve the lives of patients with inflammatory diseases and cancer.
SOURCE:AGIPNEWS
